US00773J2024
© Globe Newswire
08.01.2026
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that Spyre’s indepe...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
04.11.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
24.10.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
News Preview
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the ACR Convergenc...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
News Preview
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseas...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
News Preview
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.10.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
News Preview
WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced scienti...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-med...
Themefolio
Profiler
Peergroup
© PR Newswire
17.06.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
News Preview
SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more than 3-fold greater than first-generation anti-TL1A antibodies
SKYLINE-UC platform study evaluating three optimized monotherapies and three potentiall...
Themefolio
Profiler
Peergroup
© PR Newswire
16.06.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
News Preview
WALTHAM, Mass., June 16, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced it will rep...
Themefolio
Profiler
Peergroup
© PR Newswire
06.06.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., June 6, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
28.05.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
News Preview
WALTHAM, Mass., May 28, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, t...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
News Preview
On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts in 2026 & 2027
Reported extended follow-up Phase 1 data for SPY001, supporting that the molecule is well tolerated, has a pharmacokinetic ("PK") profile enabling quarterly or bia...
Themefolio
Profiler
Peergroup
© PR Newswire
05.05.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
News Preview
SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD)
SPY001 pharmacokinetic (PK) data up to eight months continues to support a potential best-in-class profile, including a half-life more than three times that of vedolizumab
SPY001 pharmacodynamic (PD) data up to eight months sho...
Themefolio
Profiler
Peergroup
© PR Newswire
02.05.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., May 2, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated d...
Themefolio
Profiler
Peergroup
© PR Newswire
04.04.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
News Preview
Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience over first-generation anti-IL-23 monoclonal antibodies
Interim pharmacokinetic and safety data from healthy volunteers for SPY003 anticipatedin the second half of 2025
Subject t...
Themefolio
Profiler
Peergroup
© PR Newswire
07.03.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
News Preview
Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million public offering
Continued execution towards expected milestones across portfolio, with interim Phase 1 data readouts for SPY002 and SPY003 on-track for the second quarter and second ha...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
News Preview
WALTHAM, Mass., Feb. 25, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that manage...
Themefolio
Profiler
Peergroup
© PR Newswire
19.02.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
News Preview
WALTHAM, Mass., Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases,...
Themefolio
Profiler
Peergroup
© PR Newswire
07.02.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Feb. 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of IBD and other imm...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
News Preview
Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025
Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025
Phase 2 platform trial in ulcerative colitis (UC) remains on track for initiation in mid-2025 with SPY001 (α4β7), followed by SPY002 (TL1A), SPY003 (IL...
Themefolio
Profiler
Peergroup
© PR Newswire
03.01.2025
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowe...
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Added to the Nasdaq Biotechnology Index
News Preview
WALTHAM, Mass., Dec. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today a...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowe...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
News Preview
Spyre is concurrently advancing two anti-TL1A molecules into first-in-human studies
Preclinical data for both SPY002 molecules demonstrate picomolar potency and potential for quarterly or twice-yearly dosing, suggesting opportunity for improved efficacy and convenience over first-generation anti-TL1As which are dosed every two to four weeks
Inter...
Themefolio
Profiler
Peergroup
© PR Newswire
25.11.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
News Preview
WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today a...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
News Preview
WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bow...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
News Preview
WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bow...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potentia
News Preview
SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class
SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase relative to vedolizumab, supporting potential Q6M maintenance dosing with a single subcutaneous (SC) injection
Planned Phase 2 induction regimen targets drug concentrations in quartile...
Themefolio
Profiler
Peergroup
© PR Newswire
11.11.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
News Preview
WALTHAM, Mass., Nov. 11, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bow...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024
Presented new data on SPY003, a potential best-in-class half-life extended anti-IL-23 antibody, demonstrating robust preclinical...
Themefolio
Profiler
Peergroup
© PR Newswire
01.11.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Nov. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowe...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
News Preview
WALTHAM, Mass., Oct. 30, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today a...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
News Preview
SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025
New data on SPY003 presented at UEGW demonstrating robust preclinical activity including comparable potency and a greater than three-fold extension in half-life in NHPs relative to risankizumab1. Spyre portfolio now un...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Grants of Inducement Awards
News Preview
WALTHAM, Mass., Oct. 4, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowe...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
News Preview
WALTHAM, Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowe...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2024
SYRE
LISTED
NASDAQ
Spyre Therapeutics to Participate in Upcoming Investor Conference
News Preview
WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
